Riley Fadden

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib”.

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib

Nephrology Dialysis Transplantation(2020)10.1093/ndt/gfaa372

N/A

0DataRank · unranked

22 citations

Meghan Lee, Ian A. Strohbehn, Orhan Efe, Nifasha Rusibamayila, Donald F. Chute +9 more

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma

Kidney Medicine(2020)10.1016/j.xkme.2020.01.012

N/A

0DataRank · unranked

9 citations

Halla Bates, Donald F. Chute, Ian A. Strohbehn, Samuel Strohbehn, Riley Fadden +5 more

Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3116

N/A

0DataRank · unranked

0 citations

Neal P. Smith, Moshe Sade-Feldman, Dennie T. Frederick, Russell W. Jenkins, Justine V. Cohen +13 more

Evolution of delayed resistance to immunotherapy in a melanoma responder

Nature Medicine(2021)10.1038/s41591-021-01331-8

N/A

0DataRank · unranked

136 citations

Jia‐Ren Lin, Emily Robitschek, Gyulnara G. Kasumova, Alex Heyde, Alvin Shi +35 more

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma

Kidney International Reports(2022)10.1016/j.ekir.2022.08.030

N/A

0DataRank · unranked

4 citations

Ian A. Strohbehn, Sophia Zhao, Harish Seethapathy, Samuel D. Strohbehn, Paul Hanna +7 more

Soluble and cell-based markers of immune checkpoint inhibitor associated nephritis

medRxiv(2022)10.1101/2022.10.13.22280966

N/A

0DataRank · unranked

3 citations

Qiyu Wang, Harish Seethapathy, Daiana Moreno, Destiny Harden, R. Neal Smith +13 more

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

Journal of the American Academy of Dermatology(2023)10.1016/j.jaad.2023.02.017

N/A

0DataRank · unranked

8 citations

Guihong Wan, Nga Nguyen, Hannah Rashdan, Shijia Zhang, Wenxin Chen +9 more

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007675

N/A

0DataRank · unranked

27 citations

Yevgeniy R. Semenov, Allireza Alloo, Daniel Q. Bach, Allison Betof Warner, Amina Bougrine +36 more